Skip to content

Evaluation of CF Patient Perception of Symptom Improvement Following Inhaled Antibiotic Treatment

Evaluation of CF Patient Perception of Symptom Improvement Following Inhaled Antibiotic Treatment

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12605000602628
Acronym
MCID
Enrollment
15
Registered
2005-10-05
Start date
2005-07-09
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Use of Inhaled Tobramycin Solution (TOBI) for a period of 28 days.

Sponsors

Corus Pharma
Lead SponsorCommercial sector/Industry

Study design

Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
6 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Diagnosis of CF and chronic PA infection (defined as cultures positive for PA for > 6 months, including most recent culture). Have adequate understanding of English to give informed consent and follow study procedures. Patient must have completed their most recent course of TOBI or aerosolized tobramycin solution or any other aerosolized antibiotic at least 28 days prior to study entry. Parent/guardian of children 6 to 13 years old must agree to complete the CFQ-R and Global Rating of Change Questionnaires. Patient's physician must have decided to prescribe a 28 day course of TOBI for treatment of clinical symptoms (increased cough, increased sputum production/chest congestion, decreased exercise tolerance, or decreased appetite).

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026